Incyte Corporation
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000BNPSQ9
INCY
Incyte Corporation
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Incyte Corporation
ISIN
US45337C1027
TICKER
INCY
MIC
XNAS
REUTERS
INCY.OQ
BLOOMBERG
INCY US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Sa., 14.09.2024
Incyte
US45337C1027
Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced solid tumors. The trial results, presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) with new, updated data shared during the Company’s investor...
Sa., 14.09.2024
Incyte
US45337C1027
Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-303/InterAACT2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy (carboplatin–paclitaxel) for the treatment of adults with inoperable locally recurrent or metastatic squamo...
Mo., 09.09.2024
Incyte
US45337C1027
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 11,497 shares of the Company’s common stock to 14 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of September 3, 2024, and were approved...
Mi., 21.08.2024
Incyte
US45337C1027
Incyte (Nasdaq: INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.
"The data at ESMO underscore the progress across our oncology portfolio and the potential to impact patients whe...
Do., 15.08.2024
Incyte
US45337C1027
Incyte (Nasdaq: INCY) today announces positive topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide and rituximab compared to lenalidomide and rituximab alone in patients w...
Mi., 14.08.2024
Incyte
US45337C1027
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients...
Di., 13.08.2024
Incyte
US45337C1027
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:
Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 12:45 pm (EDT)
Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 10:45 am (EDT)
Cantor Global Healthca...
Informationen zu Product Placements
